Dermaliq Therapeutics
Dr. Schlüter is the CFO and a co-founder of Dermaliq. He serves as Dermaliq’s Chairman of the Board of Directors. In parallel, Dr. Schlüter continues serving as Novaliq’s CFO, a position he has held since 2015. Prior to this Dr. Schlüter was CFO of CureVac GmbH from 2010 to 2015 where he was instrumental in the transformation of a 70 employee R&D-driven company to a 170-employee customer-centric and value-focused corporation that entered into several strategic partnerships with in-house cGMP-manufacturing. During his time at CureVac the company’s value increased more than tenfold and reached unicorn status with a value of more than $1bn. During the past 15 years in Biotech/Pharma he secured more than $400m cash for the organizations he served. Dr. Schlüter has 25+ years of professional experience within the fields of Finance and Life Sciences. He holds a PhD in computational finance and also studied business. administration.
This person is not in any teams
This person is not in any offices
Dermaliq Therapeutics
Dermaliq is developing the next generation of skin care therapies to enhance targeted penetration into skin tissues and to reduce unwanted side effects for millions of patients